Why Seegene and Alteogen Stocks Fell 17%+ as KOSDAQ Slipped 0.8%
Seegene fell 20.81% and Alteogen 16.81% on Nov. 9 while KOSDAQ lost 0.82%. Seegene has an earnings disclosure behind it. Alteogen has only press reports on U.S. drug pricing.

Seoul — Seegene closed down 20.81% at 24,550 won on Nov. 9. Alteogen closed down 16.81% at 166,800 won. KOSPI fell 0.81% and KOSDAQ fell 0.82% the same day. Seegene has an earnings disclosure from the previous session behind its drop. Alteogen has no company filing that explains today's fall.

At a glance
| Stock | Why it fell | Verdict | Basis | What to check next |
|---|---|---|---|---|
| Seegene | Q3 operating profit below expectations. Reported block deal plan by related parties | Company issue confirmed | Disclosure confirmed (block deal: press only) | Any block deal filing, Q4 results |
| Alteogen | Reports that the U.S. government will put subcutaneous drugs under price negotiation | Reason not confirmed | Press only | Details of the U.S. policy, company filings |
Seegene: down 28% in two days, with an earnings disclosure

Seegene filed preliminary consolidated operating results as a fair disclosure on the morning of Nov. 6. In DART filings from the past seven days, this is the one that bears directly on the drop. The stock fell 9.12% on Nov. 6 and another 20.81% on Nov. 9, roughly 28% over the two days. Over five sessions it is down 24.6%. It sits 36.7% below its three-month closing high of 38,800 won.
Press reports fill in the detail. Business Post said Q3 operating profit missed expectations and net income turned to a loss. News1 pointed to weaker profitability from the stronger won. Financial News and News1 also cited a possible block deal by related parties. The block deal rests on press reports only. No such filing appears in the past seven days of disclosures.
There are facts on the other side. Medical Observer reported Q3 revenue of 123.1 billion won, up 8% from a year earlier. Other reports cite growth in non-respiratory diagnostic products. In Paper Trail's check, Seegene passed four of five earnings-strength items: profitable, positive free cash flow, manageable debt and revenue growth. It missed the 10% ROE test. Revenue growth is 19.2%. Sales rose, but profit fell short.
How far has it fallen? RSI (14-day) is 8.4, a short-term oversold zone. The stock sits at 17% of its 52-week range and 13.1% below its 200-day average. Volume was 6.4 times normal. These figures describe the size of the drop, not a signal to buy.
Alteogen: down 50%, but today's reason is not in a filing

Alteogen is 50.9% below its three-month high of 339,500 won. It is down 49.1% since Aug. 11 and 21.9% over five sessions. Reports from Maeil Business and Newspim tie the Nov. 9 drop to U.S. drug price concerns. They say Washington will put subcutaneous injections under price negotiation, as it has for intravenous drugs. The company was reported to say the competitiveness of Hybrozyme remains intact.
No DART filing in the past seven days addresses this directly. The only Nov. 9 filings are two notices that the stock's futures and options hit price-limit expansion levels on the downside. The cause rests on press reports, and this data cannot show how much the policy would affect the company's earnings. The verdict is reason not confirmed.
The other side gets equal weight. Preliminary consolidated results were filed on Nov. 3, and revenue growth in the check is 269.5%. Four of five earnings-strength items pass; only free cash flow is not positive. There were also two securities issuance result filings each on Oct. 14 and Oct. 30. The titles alone do not show what was issued, so the details need checking. The market backdrop is weak too. News1 reported foreign investors sold 13.5 trillion won over seven sessions.
How far has it fallen? RSI is 24.8, a short-term oversold zone. The stock sits at 0% of its 52-week range, 60.8% below the 52-week high and 38.4% below its 200-day average. Volume was 14.2 times normal.
What to check next
For Seegene, watch whether the block deal appears as a filing and whether profit recovers next quarter. For Alteogen, check the scope of the U.S. policy, any company statement filed with DART, and what the October securities issuance filings covered. The company is also attending BIO-Europe from Nov. 9.